A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in

Clinical Trial Description

This is a Phase 2, randomized, open-label, 2-arm study designed to evaluate the efficacy and safety of prescribed drug holidays of duvelisib treatment in subjects with R/R iNHL who have received at least 1 prior systemic therapy. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04883437` - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Phase 2
Completed	`NCT04136756` - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT00075478` - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 3
Completed	`NCT02242045` - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)	Phase 1
Completed	`NCT01231412` - Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Phase 3
Active, not recruiting	`NCT02566304` - Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Recruiting	`NCT04223765` - Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.	Phase 1
Active, not recruiting	`NCT03035331` - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05876923` - The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients	N/A
Completed	`NCT00723099` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Phase 2
Active, not recruiting	`NCT03105336` - A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	Phase 2
Withdrawn	`NCT04372641` - Testing the Safety of CB-5339 in Patients With Cancer	Phase 1
Completed	`NCT01882803` - A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma	Phase 2
Active, not recruiting	`NCT04323956` - Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Phase 1
Active, not recruiting	`NCT04464200` - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers	Phase 1
Recruiting	`NCT05783596` - Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	Phase 2
Recruiting	`NCT05336409` - A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies	Phase 1
Active, not recruiting	`NCT03749018` - Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma	Phase 2
Active, not recruiting	`NCT03884998` - Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma	Phase 1
Terminated	`NCT01944943` - Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 2

NCT number	NCT04038359
Study type	Interventional
Source	SecuraBio
Contact
Status	Completed
Phase	Phase 2
Start date	September 24, 2019
Completion date	July 24, 2023

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma — TEMPO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms